Índices compuestos para evaluar la actividad de la enfermedad y el daño estructural en pacientes con lupus eritematoso: revisión sistemática de la literatura
I Castrejón, I Rúa-Figueroa, MP Rosario… - Reumatología Clínica, 2014 - Elsevier
Objetivos Determinar que índices compuestos serían los más apropiados para la evaluación
de la actividad o el daño estructural en pacientes con lupus eritematoso sistémico (LES). …
de la actividad o el daño estructural en pacientes con lupus eritematoso sistémico (LES). …
Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study
…, D Martinez-Lopez, I Castrejón… - Annals of the …, 2020 - ard.bmj.com
Objectives The impact of inflammatory rheumatic diseases on COVID-19 severity is poorly
known. Here, we compare the outcomes of a cohort of patients with rheumatic diseases with a …
known. Here, we compare the outcomes of a cohort of patients with rheumatic diseases with a …
Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases
Background The susceptibility of patients with rheumatic diseases and the risks or benefits
of immunosuppressive therapies for COVID-19 are unknown. Methods We performed a …
of immunosuppressive therapies for COVID-19 are unknown. Methods We performed a …
[HTML][HTML] Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes
…, J Rivera, J Molina Collada, I Castrejón… - Rheumatology …, 2020 - Springer
Objective To describe clinical characteristics of patients with rheumatic and musculoskeletal
diseases (RMDs) and immunosuppressive therapies with Coronavirus disease 2019 (…
diseases (RMDs) and immunosuppressive therapies with Coronavirus disease 2019 (…
Criterios de cribado de la enfermedad pulmonar intersticial difusa asociada a la artritis reumatoide: propuesta de expertos basada en metodología Delphi
…, AM Ortiz, C Sabater-Abad, I Castrejón… - Reumatología …, 2023 - Elsevier
Objetivo Elaborar una propuesta multidisciplinar de criterios de cribado de enfermedad
pulmonar intersticial difusa (EPID) en pacientes con artritis reumatoide (AR) y, a la inversa, que …
pulmonar intersticial difusa (EPID) en pacientes con artritis reumatoide (AR) y, a la inversa, que …
Recomendaciones SER-SEPAR para el manejo de la enfermedad pulmonar intersticial difusa asociada a la artritis reumatoide. Parte 2: tratamiento
…, C Valenzuela, MÁA Hernández, I Castrejón… - Reumatología …, 2022 - Elsevier
Objetivo Elaborar unas recomendaciones multidisciplinares para mejorar el manejo de la
enfermedad pulmonar intersticial difusa asociada a la artritis reumatoide (EPID-AR). Métodos …
enfermedad pulmonar intersticial difusa asociada a la artritis reumatoide (EPID-AR). Métodos …
MDHAQ/RAPID3 to recognize improvement over 2 months in usual care of patients with osteoarthritis, systemic lupus erythematosus, spondyloarthropathy, and gout …
I Castrejón, MJ Bergman, T Pincus - JCR: Journal of Clinical …, 2013 - journals.lww.com
… Dr Castrejón declares no financial interest. … Askanase AD, Castrejón I, Pincus T. Quantitative
data for care of patients with systemic lupus erythematosus in usual clinical settings: a …
data for care of patients with systemic lupus erythematosus in usual clinical settings: a …
Importance of patient history and physical examination in rheumatoid arthritis compared to other chronic diseases: results of a physician survey
I Castrejón, L McCollum, MD Tanriover… - Arthritis care & …, 2012 - Wiley Online Library
Objective To survey physicians' opinions concerning the relative importance of 5 clinical
encounter components—vital signs, patient history, physical examination, laboratory tests, and …
encounter components—vital signs, patient history, physical examination, laboratory tests, and …
Update on methotrexate as the anchor drug for rheumatoid arthritis.
…, KA Gibson, I Castrejón - Bulletin of the Hospital for …, 2013 - search.ebscohost.com
Methotrexate has become the" anchor drug" for rheumatoid arthritis (RA), taken by many
more patients than any other disease modifying anti-rheumatic drug (DMARD) or biological …
more patients than any other disease modifying anti-rheumatic drug (DMARD) or biological …
Evidence that the Strategy is More Important than the Agent to Treat Rheumatoid Arthritis.
T Pincus, I Castrejón - Bulletin of the Hospital for Joint …, 2013 - search.ebscohost.com
Eight major" strategy trials" in rheumatoid arthritis (RA) are reviewed, with protocol-driven
escalation of combinations of methotrexate and other small molecule non-biological disease …
escalation of combinations of methotrexate and other small molecule non-biological disease …
